Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting
New in vivo data demonstrate the broad anti-inflammatory activity of KT-474 and its superiority compared to a clinically active small...